argenx Announces Annual General Meeting of Shareholders on May 7, 2024
26 Marzo 2024 - 9:00PM
March 26, 2024
Amsterdam, the Netherlands –
argenx SE (Euronext & Nasdaq: ARGX), a global immunology
company committed to improving the lives of people suffering from
severe autoimmune diseases, today announced that the Annual General
Meeting of shareholders will be held at 13:00 CET on Tuesday, May
7, 2024 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701,
1118 BN Schiphol, the Netherlands.The shareholders and all other
persons with meeting rights are invited to attend the Annual
General Meeting of shareholders. The formal notice of convocation
(including information on attending the meeting in person or by
proxy, requirements for notification and registration for the
meeting and regarding the e-voting system) is available on the
argenx website www.argenx.com and on www.abnamro.com/evoting.
The company’s annual report for the financial
year ended December 31, 2023 is now available on its website
www.argenx.com/investors/financial-reports.
AgendaIn addition to recurrent
items on the agenda, such as the discussion and adoption of the
2023 annual accounts, an advisory vote on the 2023 remuneration
report, the discharge of the directors for their duties performed
in 2023 and the authorization of the Board of Directors to issue
shares and to limit or exclude pre-emptive rights in relation
thereto, it is proposed to appoint Dr. Brian L. Kotzin as
non-executive director to the Board of Directors, re-appoint Peter
Verhaeghe and Pamela Klein as non-executive directors to the Board
of Directors, adopt a new remuneration policy, appoint Deloitte
Accountants B.V. for the 2024 financial year and appoint Ernst
& Young Accountants for the 2025 financial year and to
partially amend the articles of association of argenx.
The full agenda for the meeting as well as all
ancillary documents relevant for the meeting are available via the
argenx website and are also available for inspection at the argenx
offices. A free copy thereof may also be obtained by e-mailing
legal@argenx.com. argenx would like to encourage shareholders to
use the voting by (electronic) proxy option as referred to in the
convocation.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx developed and is commercializing the first approved neonatal
Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the
UK, Canada and China. The Company is evaluating efgartigimod in
multiple serious autoimmune diseases and advancing several earlier
stage experimental medicines within its therapeutic franchises. For
more information, visit www.argenx.com and follow us
on LinkedIn, Twitter, and Instagram.
For further information, please
contact:
Media:
Ben PetokBpetok@argenx.com
Investors:
Alexandra Roy (US) aroy@argenx.com
Lynn Elton (EU) lelton@argenx.com
Grafico Azioni argenx (NASDAQ:ARGX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni argenx (NASDAQ:ARGX)
Storico
Da Nov 2023 a Nov 2024
